Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Orphan in need of adoption

Abstract:
Nano therapy for ovarian cancer will enable superior tumor accumulation and retention of radioactivity, resulting in better therapuetic efficacy than existing standards of care.

Orphan in need of adoption

Philadelphia, PA | Posted on December 8th, 2006

Twenty thousand new cases of ovarian cancer are diagnosed in the United States each year. More than 75% of these patients are women with late stage ovarian cancer. The prognosis for this group is very poor: only 30% will survive five years or longer.

Even treatment for ovarian cancer can be devastating to a patient's quality of life. Treatment commonly involves invasive surgery followed by extensive chemotherapy, both of which can be physically and emotionally traumatic.

Under funding received from The Nanotechnology Institute and the National Cancer Institute, University of Pennsylvania Scientists have created a nanotechnology-based radiopharmaceutical that could potentially improve the treatment of ovarian cancer.

The proprietary platform technology specifically targets cancer cells via the folate receptor pathway, minimizing damage to surrounding non-cancerous cells. In principle, the drug will enable a higher tumor radiation dose than is possible with other radiotherapeutics, which do not deliver enough radiation to be useful for treatment.

Unfortunately, despite tremendous laboratory progress, this technology may never reach the patients who need it most. The reason is that the market opportunity for ovarian cancer is small (~$75M/year) - too small to justify development by a large multinational corporation.

"This is a platform technology with enormous potential, but its early stage means there is also enormous clinical risk," says Dr. Brian Smith, a co-inventor of the technology. "Our work with Greg Adams at the Fox Chase Cancer Center is promising, but it suggests the need for additional experiments."

Usually at this stage of development, a sponsoring company would invest and work with the scientist to further the research. However, the small market size is a significant barrier to attracting would-be investors. Dr. Smith also hopes to keep the drug affordable, launching at a price of around $5,000 instead of the $50,000 that could be charged for this type of therapy.

"What we need is an angel with personal interest," says Hugo Fitzgerald, Manager of Nanotechnology and Licensing at the University of Pennsylvania. "We have an adequate IP portfolio to justify the creation of a small start up, what we lack is the outside management to champion it and push it out of the laboratory and into the FDA approval process."

The therapeutic would likely qualify for tax credits and marketing exclusivity under the Orphan Drug Act, priority FDA review, and accelerated FDA approval. Follow on applications could include treatments for various other cancers as well as a related radiopharmaceutical for diagnostic imaging.

If interested in working with or supporting the research, please contact:

Hugo FitzGerald
Manager Nanotechnology and Licensing
Center for Technology Transfer
University of Pennsylvania

####

For more information, please click here

Contacts:
Contact: Hugo FitzGerald
Phone: 215 573 4307
Fax:
E-mail:

Copyright © University of Pennsylvania

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017

Nanomedicine

'Upconverted' light has a bright future: Rice University professor developing plasmon-powered devices for medicine, security, solar cells July 17th, 2017

Researchers revolutionize vital conservation tool with use of gold nanotechnology and lasers: Cryopreservation study results have sweeping implications for wildlife conservation and human health July 15th, 2017

Nanomedicine opens door to precision medicine for brain tumors July 12th, 2017

Killing cancer in the heat of the moment: A new method efficiently transfers genes into cells, then activates them with light. This could lead to gene therapies for cancers July 9th, 2017

Announcements

Here's a tip: Indented cement shows unique properties: Rice University models reveal nanoindentation can benefit crystals in concrete July 20th, 2017

Tokyo Institute of Technology research: Antiaromatic molecule displays record electrical conductance July 19th, 2017

Harnessing light to drive chemical reactions July 19th, 2017

Nanoparticles could spur better LEDs, invisibility cloaks July 19th, 2017

Human Interest/Art

Weizmann Institute of Science Presents: Weizmann Wonder Wander - 4G - is Online June 21st, 2016

Call for NanoArt and Art-Science-Technology Papers June 9th, 2016

Scientists propose non-animal tools for assessing the toxicity of nanomaterials: Particle and Fibre Toxicology publishes recommendations from expert group meeting April 26th, 2016

Are humans the new supercomputer?Today, people of all backgrounds can contribute to solving serious scientific problems by playing computer games. A Danish research group has extended the limits of quantum physics calculations and simultaneously blurred the boundaries between mac April 14th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project